Search

Author/Creator Paolini, John F

1. Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Issue 4 (19th January 2022)

Authors:
Corbera-Bellalta, Marc; Alba-Rovira, Roser; Muralidharan, Sujatha; Espígol-Frigolé, Georgina; Ríos-Garcés, Roberto; Marco-Hernández, Javier; Denuc, Amanda; Kamberovic, Farah; Pérez-Galán, Patricia; Joseph, Alexandra; D'Andrea, Annalisa; Bondensgaard, Kent; Cid, Maria C; Paolini, John F
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 4(2022)
Page Start:
524
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Issue 5 (9th March 2022)

Authors:
Cid, Maria C; Unizony, Sebastian H; Blockmans, Daniel; Brouwer, Elisabeth; Dagna, Lorenzo; Dasgupta, Bhaskar; Hellmich, Bernhard; Molloy, Eamonn; Salvarani, Carlo; Trapnell, Bruce C; Warrington, Kenneth J; Wicks, Ian; Samant, Manoj; Zhou, Teresa; Pupim, Lara; Paolini, John F
Journal:
Annals of the rheumatic diseases
Issue:
Volume 81:Issue 5(2022)
Page Start:
653
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. (August 2020)

Authors:
De Luca, Giacomo; Cavalli, Giulio; Campochiaro, Corrado; Della-Torre, Emanuel; Angelillo, Piera; Tomelleri, Alessandro; Boffini, Nicola; Tentori, Stefano; Mette, Francesca; Farina, Nicola; Rovere-Querini, Patrizia; Ruggeri, Annalisa; D'Aliberti, Teresa; Scarpellini, Paolo; Landoni, Giovanni; De C...
Journal:
Lancet
Issue:
Volume 2:Number 8(2020)
Page Start:
e465
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. (June 2021)

Authors:
Cremer, Paul C; Abbate, Antonio; Hudock, Kristin; McWilliams, Carla; Mehta, Jinesh; Chang, Steven Y; Sheng, Calvin C; Van Tassell, Benjamin; Bonaventura, Aldo; Vecchié, Alessandra; Carey, Brenna; Wang, Qiuqing; Wolski, Katherine E; Rajendram, Prabalini; Duggal, Abhijit; Wang, Tisha S; Paolini, Jo...
Journal:
Lancet
Issue:
Volume 3:Number 6(2021)
Page Start:
e410
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗